How and why to screen for CYP2D6 interindividual variability in patients under pharmacological treatments

Current Drug Metabolism

Volumn 11, Issue 3, 2010, Pages 276-282

  De Gregori, Manuela ^a,b   Allegri, Massimo ^b   De Gregori, Simona ^b   Garbin, Giulia ^a   Tinelli, Carmine ^b   Regazzi, Mario ^b   Govoni, Stefano ^a   Ranzani, Guglielmina Nadia ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Clinical outcome; Customized therapy; CYP2D6 polymorphisms; Drug metabolism; Genotyping techniques; Interindividual variability; Phenotypes

Indexed keywords

CYTOCHROME P450 2D6;

ALLELE; DNA SEQUENCE; ENZYME SUBSTRATE; FRAMESHIFT MUTATION; GENE DELETION; GENE INSERTION; GENE MUTATION; GENE TECHNOLOGY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MICROARRAY ANALYSIS; PHARMACEUTICAL CARE; PHENOTYPE; PROTEIN ANALYSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

CYTOCHROME P-450 CYP2D6; GENETIC TESTING; GENETIC VARIATION; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 77951759129     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920010791196274     Document Type: Review

References (60)

1. Mahgoub, A.; Idle, J.R.; Dring, L.G.; Lancaster, R.; Smith, R.L. Polymorphic hydroxylation of debrisoquine in man. Lancet, 1977, 2(8038), 584-586.
2. Eichelbaum, M.; Spannbrucker, N.; Steinke, B.; Dengler, H.J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur. J. Clin. Pharmacol., 1979, 16(3), 183-187.
3. Dayer, P.; Gasser, R.; Gut, J.; Kronbach, T.; Robertz, G.M.; Eichelbaum, M.; Meyer, U.A. Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism) - increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1′-hydroxylation in poor metabolizers. Biochem. Biophys. Res. Commun., 1984, 125(1), 374-380.
4. Govoni, S.; Regazzi, M.; Ranzani G.N. Pain and the pharmacogenetics at the fuzzy border between pain physiopathology and pain treatment. Eur. J. Pain, 2008, 2, S5-S12.
5. Lötsch, J.; Geisslinger, G.; Tegeder, I. Genetic modulation of the pharmacological treatment of pain. Pharmacol. Ther., 2009, 124(2), 168-184.
6. Zanger, U.M.; Turpeinen, M.; Klein, K.; Schwab, M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal. Chem., 2008, 392(6), 1093-1108.
7. Tomaszewski, P.; Kubiak-Tomaszewska, G.; Łukaszkiewicz, J.; Pachecka, J. Cytochrome P450 polymorphism - molecular, metabolic, and pharmacogenetic aspects. III. Influence of CYP genetic polymorphism on population differentiation of drug metabolism phenotype. Acta. Pol. Phar., 2008, 65(3), 319-329.
8. Stamer, U.M.; Stüber, F. Genetic factors in pain and its treatment. Curr. Opin. Anaesthesiol., 2007, 20(5), 478-484. (Pubitemid 47415138)
9. Obach, R.S.; Walsky, R.L.; Venkatakrishnan, K.; Gaman, E.A.; Houston J.B.; Tremaine, L.M. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J. Pharmacol. Exp. Ther., 2006, 316(1), 336-348.
10. Božina, N.; Bradamante, V.; Lovrić, M. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol, 2009, 60(2), 217-242.
11. Ingelman-Sundberg, M.; Sim, S.C.; Gomez, A.; Rodriguez-Antona, C. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther., 2007, 116(3), 496-526. (Pubitemid 350116943)
12. Foster, A.; Mobley, E.; Wang, Z. Complicated pain management in a CYP450 2D6 poor metabolizer. Pain Pract., 2007, 7(4), 352-356. (Pubitemid 350142307)
13. Zhou, S.F.; Liu J.P.; Lai X.S. Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. Curr. Med. Chem., 2009, 16(21), 2661-2685.
14. Pelkonen, O.; Turpeinen, M.; Hakkola, J.; Honkakoski, P.; Hukkanen, J.; Raunio, H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch. Toxicol., 2008, 82(10), 667-715.
15. Jannetto, P.J.; Bratanow, N.C. Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management. Pharmacogenomics, 2009, 10(7), 1157-1167.
16. Ingelman-Sundberg, M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J., 2005, 5(1), 6-13. (Pubitemid 40220611)
17. Stamer, U.M.; Bayerer, B.; Wolf, S.; Hoeft, A.; Stüber, F. Rapid and reliable method for cytochrome P450 2D6 genotyping. Clin. Chem., 2002, 48(9), 1412-1417.
18. Arneth, B.; Shams, M.; Hiemke C.; Härtter S. Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene. Clin. Biochem., 2009, 42(12), 1282-1290.
19. de Leon, J.; Susce, M.T.; Johnson, M.; Hardin, M; Lorraine M.; Shao A.; Antonette C.P. Allen, A.C.P.; Chiafari, F.A.; Hillman, G.; Nikoloff, D.M. DNA microarray technology in the clinical environment: the amplichip CYP450 test for CYP2D6 and CYP2C19 genotyping. CNS Spectr., 2009, 14(1), 19-34.
20. Dorado, P.; Cáceres, M.; Pozo-Guisado, E.; Wong, M.L.; Licinio, J.; Llerena, A. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. Biotechniques, 2005, 39(10 Suppl), S571-574.
21. Zanger, U.M.; Raimundo, S.; Eichelbaum, M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg's Arch Pharmacol., 2004, 369(1), 23-37. (Pubitemid 38161221)
22. Heim, M.; Meyer, U.A. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet, 1990, 336(8714), 529-532.
23. Broly, F.; Marez, D.; Sabbagh, N.; Legrand, M.; Millecamps, S.; Lo Guidice, J.M.; Boone, P.; Meyer, U.A. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics, 1995, 5(6), 373-384.
24. Marez, D.; Legrand, M.; Sabbagh, N.; Guidice, J.M.; Spire, C.; Lafitte, J.J.; Meyer, U.A.; Broly, F. Polymorhpism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics, 1997, 7(3), 193-202. (Pubitemid 27290633)
25. Stüven, T.; Griese, E.U.; Kroemer, H.K.; Eichelbaum, M.; Zanger, U.M. Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. Pharmacogenetics, 1996, 6(5), 417-421. (Pubitemid 26380097)
26. Gaedigk, A.; Gotschall, R.R.; Forbes, N.S.; Simon, S.D.; Kearns, G.L.; Leeder, J.S. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics, 1999, 9(6), 669-682.
27. Labuda, D.; Krajinovic, M.; Richer, C.; Skoll, A.; Sinnett, H.; Yotova, V.; Sinnett, D. Rapid detection of CYP1A1, CYP2D6, and NAT variants by multiplex polymerase chain reaction and allele-specific oligonucleotide assay. Anal. Biochem., 1999, 275(1), 84-92.
28. Raimundo, S; Fischer, J; Eichelbaum, M; Griese, E.U.; Schwab, M; Zanger, U.M. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics, 2000, 10(7), 577-581.
29. Hersberger, M.; Marti-Jaun, J.; Rentsch, K.; Hänseler, E. Rapid Detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 Alleles by Tetra-Primer PCR and of the CYP2D6*5 Allele by Multiplex Long PCR. Clin. Chem., 2000, 46(8 Pt 1), 1072-1077. (Pubitemid 30643307)
30. Müller, B.; Zöpf, K.; Bachofer, J.; Steimer, W. Optimized strategy for rapid cytochrome P450 2D6 genotyping by real-time long PCR. Clin. Chem., 2003, 49(10), 1624-1631. (Pubitemid 37194216)
31. Schaeffeler, E.; Schwab, M.; Eichelbaum, M.; Zanger, U.M. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum. Mutat., 2003, 22(6),476-485.
32. Gaedigk, A.; Simon, S.D.; Pearce, R.E.; Bradford, L.D.; Kennedy, M.J.; Leeder, J.S. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol Ther., 2008, 83(2),234-242.
33. Murphy, G.M.; Pollock, B.G.; Kirshner, M.A.; Pascoe, N.; Cheuk, W.; Mulsant, B.H.; Reynolds, C.F. CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. Neuropsychopharmacology, 2001, 25(5), 737-743.
34. Gough, A.C.; Miles, J.S.; Spurr, N.K.; Moss, J.E.; Gaedigk, A.; Eichelbaum, M.; Wolf, C.R. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature, 1990, 347(6295),773-776. (Pubitemid 20370724)
35. Sakuyama, K.; Sasaki, T.; Ujiie, S.; Obata, K.; Mizugaki, M.; Ishikawa, M.; Hiratsuka, M. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metab. Dispos., 2008, 36(12), 2460-2467.
36. Garcia-Barceló, M.; Chow, L.Y.; Chiu, H.F.; Wing, Y.K.; Lee, D.T.; Lam, K.L.; Waye, M.M. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin. Chem., 2000, 46(1), 18-23. (Pubitemid 30090955)
37. Furuta,T.; Shirai, N.; Sugimoto, M.; Ohashi, K.; Ishizaki, T. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics, 2004, 5(2),181-202.
38. Burmester, J.K.; Sedova, M.; Shapero, M.H.; Mansfield, E. DMET microarray technology for pharmacogenomics-based personalized medicine. Methods Mol. Biol., 2010, 632, 99-124.
39. Deeken, J. The Affymetrix DMET platform and pharmacogenetics in drug development. Curr. Opin. Mol. Ther., 2009, 11(3), 260-268.
40. Daly, T.M.; Dumaual, C.M.; Miao, X.;, Farmen, M.W.; Njau, R.K.; Fu, D.J.; Bauer, N.L.; Close, S.; Watanabe, N.; Bruckner, C.; Hardenbol, P.; Hockett, R.D. Multiplex assay for comprehensive genotyping of genes involved in drug metabolism, excretion, and transport. Clin. Chem., 2007, 53(7), 1222-1230.
41. Rousseau, F.; Gancberg, D.; Schimmel, H.; Neumaier, M.; Bureau, A.; Mamotte, C.; van Schaik, R.; Payne, D.; Pazzagli, M.; Young, I. Considerations for the development of a reference method for sequencing of haploid DNA - an opinion paper on behalf of the IFCC Committee on Molecular Diagnostics, International Federation of Clinical Chemistry and Laboratory Medicine. Clin. Chem. Lab. Med., 2009, 47(11), 1343-1350.
42. International HapMap Consortium, Frazer, K.A.; Ballinger, D.G.; Cox, D.R.; Hinds, D.A.; Stuve, L.L.; Gibbs, R.A.; Belmont, J.W.; Boudreau, A.; Hardenbol, P.; Leal, S.M.; Pasternak, S.; Wheeler, D.A.; Willis, T.D.; Yu, F.; Yang, H.; Zeng, C.; Gao, Y.; Hu, H.; Hu, W.; Li, C.; Lin, W.; Liu, S.; Pan, H.; Tang, X.; Wang, J.; Wang, W.; Yu, J.; Zhang, B.; Zhang, Q.; Zhao, H.; Zhao, H.; Zhou, J.; Gabriel, S.B.; Barry, R.; Blumenstiel, B.; Camargo, A.; Defelice, M.; Faggart, M.; Goyette, M.; Gupta, S.; Moore, J.; Nguyen, H.; Onofrio, R.C.; Parkin, M.; Roy, J.; Stahl, E.; Winchester, E.; Ziaugra, L.; Altshuler, D.; Shen, Y.; Yao, Z.; Huang, W.; Chu, X.; He, Y.; Jin, L.; Liu, Y.; Shen, Y.; Sun, W.; Wang, H.; Wang, Y.; Wang, Y.; Xiong, X.; Xu, L.; Waye, M.M.; Tsui, S.K.; Xue, H.; Wong, J.T.; Galver, L.M.; Fan, J.B.; Gunderson, K.; Murray, S.S.; Oliphant, A.R.; Chee, M.S.; Montpetit, A.; Chagnon, F.; Ferretti, V.; Leboeuf, M.; Olivier, J.F.; Phillips, M.S.; Roumy, S.; Sallée, C.; Verner, A.; Hudson, T.J.; Kwok, P.Y.; Cai, D.; Koboldt, D.C.; Miller, R.D.; Pawlikowska, L.; Taillon-Miller, P.; Xiao, M.; Tsui, L.C.; Mak, W.; Song, Y.Q.; Tam, P.K.; Nakamura, Y.; Kawaguchi, T.; Kitamoto, T.; Morizono, T.; Nagashima, A.; Ohnishi, Y.; Sekine, A.; Tanaka, T.; Tsunoda, T.; Deloukas, P.; Bird, C.P.; Delgado, M.; Dermitzakis, E.T.; Gwilliam, R.; Hunt, S.; Morrison, J.; Powell, D.; Stranger, B.E.; Whittaker, P.; Bentley, D.R.; Daly, M.J.; de Bakker, P.I.; Barrett, J.; Chretien, Y.R.; Maller, J.; McCarroll, S.; Patterson, N.; Pe'er, I.; Price, A.; Purcell, S.; Richter, D.J.; Sabeti, P.; Saxena, R.; Schaffner, S.F.; Sham, P.C.; Varilly, P.; Altshuler, D.; Stein, L.D.; Krishnan, L.; Smith, A.V.; Tello-Ruiz, M.K.; Thorisson, G.A.; Chakravarti, A.; Chen, P.E.; Cutler, D.J.; Kashuk, C.S.; Lin, S.; Abecasis, G.R.; Guan, W.; Li, Y.; Munro, H.M.; Qin, Z.S.; Thomas, D.J.; McVean, G.; Auton, A.; Bottolo, L.; Cardin, N.; Eyheramendy, S.; Freeman, C.; Marchini, J.; Myers, S.; Spencer, C.; Stephens, M.; Donnelly, P.; Cardon, L.R.; Clarke, G.; Evans, D.M.; Morris, A.P.; Weir, B.S.; Tsunoda, T.; Mullikin, J.C.; Sherry, S.T.; Feolo, M.; Skol, A.; Zhang, H.; Zeng, C.; Zhao, H.; Matsuda, I.; Fukushima, Y.; Macer, D.R.; Suda, E.; Rotimi, C.N.; Adebamowo, C.A.; Ajayi, I.; Aniagwu, T.; Marshall, P.A.; Nkwodimmah, C.; Royal, C.D.; Leppert, M.F.; Dixon, M.; Peiffer, A.; Qiu, R.; Kent, A.; Kato, K.; Niikawa, N.; Adewole, I.F.; Knoppers, B.M.; Foster, M.W.; Clayton, E.W.; Watkin, J.; Gibbs, R.A.; Belmont, J.W.; Muznym D.; Nazarethm L.; Sodergrenm E.; Weinstockm G,M.; Wheelerm, D.A.; Yakub, I.; Gabriel, S.B.; Onofrio, R.C.; Richter, D.J.; Ziaugra, L.; Birren, B.W.; Daly, M.J.; Altshuler, D.; Wilson, R.K.; Fulton, L.L.; Rogers, J.; Burton, J.; Carter, N.P.; Clee, C.M.; Griffiths, M.; Jones, M.C.; McLay, K.; Plumb, R.W.; Ross, M.T.; Sims, S.K.; Willey, D.L.; Chen, Z.; Han, H.; Kang, L.; Godbout, M.; Wallenburg, J.C.; L'Archevêque, P.; Bellemare, G.; Saeki, K.; Wang, H.; An, D.; Fu, H.; Li, Q.; Wang, Z.; Wang, R.; Holden, A.L.; Brooks, L.D.; McEwen, J.E.; Guyer, M.S.; Wang, V.O.; Peterson, J.L.; Shi, M.; Spiegel, J.; Sung, L.M.; Zacharia, L.F.; Collins, F.S.; Kennedy, K.; Jamieson, R.; Stewart, J. A second generation human haplotype map of over 3.1 million SNPs. Nature, 2007, 449(7164), 851-861.
43. Teichert, M.; Eijgelsheim, M.; Rivadeneira, F.; Uitterlinden, A.G.; van Schaik, R.H.; Hofman, A.; De Smet, P.A.; van Gelder, T.; Visser, L.E.; Stricker, B.H. A genome-wide association study of acenocoumarol maintenance dosage. Hum. Mol. Genet., 2009, 18(19), 3758-3768.
44. Frueh, F.W.; Amur, S.; Mummaneni, P.; Epstein, R.S.; Aubert, R.E.; DeLuca, T.M.; Verbrugge, R.R.; Burckart, G.J,; Lesko, L.J. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy, 2008, 28(8), 992-998.
45. Coller, J.K.; Christrup, L.L.; Somogyi, A.A. Role of active metabolites in the use of opioids. Eur. J. Clin. Pharmacol., 2009, 65(2),121-139.
46. Li, Y.; Kantelip, J.P.; Gerritsen-van Schieveen, P.; Davani, S. Interindividual variability of methadone response. Mol. Diagn. Ther., 2008, 12(2), 109-124.
47. Candiotti KA, Yang Z, Rodriguez Y, Crescimone A, Sanchez GC, Takacs P, Medina C, Zhang Y, Liu H, Gitlin MC. The impact of CYP2D6 genetic polymorphisms on postoperative morphine consumption. Pain Med., 2009, 10(5), 799-805.
48. Zhu, W.; Cadet, P.; Baggerman, G.; Mantione, K.J.; Stefano GB. Human white blood cells synthesize morphine: CYP2D6 modulation. J. Immunol., 2005, 175(11), 7357-7362.
49. Goetz, M.P.; Rae, J.M.; Suman, V.J.; Safgren, S.L.; Ames, M.M.; Visscher, D.W.; Reynolds, C.; Couch, F.J.; Lingle, W.L.; Flockhart, D.A.; Desta Z.; Perez, E.A.; Ingle, J.N. Pharmacogenetics of Tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol., 2005, 23(36), 9312-9318. (Pubitemid 46260189)
50. Bijl, M.J.; van Schaik, R.H.; Lammers, L.A.; Hofman, A.; Vulto, A.G.; van Gelder, T.; Stricker, B.H.; Visser, L.E. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res. Treat., 2009, 118(1), 125-130.
51. Varsaldi, F.; Miglio, G.; Scordo, M.G.; Dahl, M.L.; Villa, L.M.; Biolcati, A.; Lombardi, G. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. Eur. J. Clin. Pharmacol., 2006, 62(9), 721-726. (Pubitemid 44289502)
52. Pilotto, A.; Franceschi, M.; D'Onofrio, G.; Bizzarro, A.; Mangialasche, F.; Cascavilla, L.; Paris, F.; Matera, M.G.; Pilotto, A.; Daniele, A.; Mecocci, P.; Masullo, C.; Dallapiccola, B.; Seripa, D. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology, 2009, 73(10), 761-767.
53. Rebsamen, M.C.; Desmeules, L.; Daali, Y.; Chiappe, A.; Diemand, A.; Rey, C.; Chabert, J.; Dayer, P.; Hochstrasser, D.; Rossier, M.F. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J., 2009, 9(1), 34-41.
54. Ramón y Cajal, T.; Altés, A.; Paré, L.; del Rio, E.; Alonso, C.; Barnadas, A.; Baiget, M. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res. Treat., 2010, 119(1), 33-38.
55. Deeken, J.F.; Cormier, T.; Price, D.K.; Sissung, T.M.; Steinberg, S.M.; Tran, K.; Liewehr, D.J.; Dahut, W.L.; Miao, X.; Figg, W.D. A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. Pharmacogenomics J., 2009 Dec 29. [Epub ahead of print]
56. Mega, J.L.; Close, S.L.; Wiviott, S.D.; Shen, L.; Hockett, R.D.; Brandt, J.T.; Walker, J.R.; Antman, E.M.; Macias, W.; Braunwald, E.; Sabatine, M.S. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med., 2009, 360(4), 354-362.
57. Deverka, P.A. Pharmacogenomics, evidence, and the role of payers. Public Health Genomics, 2009, 12(3), 149-157.
58. Zhou, S.F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinet., 2009, 48(11), 689-723.
59. Zhou, S.F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin. Pharmacokinet., 2009, 48(12), 761-804.
60. Neafsey, P.; Ginsberg, G.; Hattis, D.; Sonawane, B. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity. J. Toxicol. Environ. Health, 2009, 12(5-6), 334-361.